In ₹ Crore except Per Share Latest Annual | EMCURE FY26 | MANKIND FY26 | ALKEM FY26 | TORNTPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 40.32× | 48.46× | ◆ 26.55× | 77.05× | 48.46× -17% | |
| P/B | 7.49× | 5.60× | ◆ 4.26× | 9.48× | 5.60× +34% | |
| EV/EBITDA | 20.57× | 26.84× | ◆ 20.54× | 39.37× | 26.84× -23% | |
| Market Cap | ₹37,281 Cr | ₹92,715 Cr | ₹61,102 Cr | ₹1.67L Cr | ₹92,715 Cr -60% | |
| Growth | ||||||
| Revenue CAGR 3Y | — | ◆ 17.73% | 8.25% | 13.27% | 13.27% | |
| Revenue CAGR 5Y | — | — | 10.09% | ◆ 11.80% | 10.95% | |
| Net Income CAGR 3Y | — | 13.96% | ◆ 32.67% | 19.75% | 19.75% | |
| Revenue YoY (latest Q) | 22.85% | 12.89% | 10.95% | ◆ 54.85% | 12.89% +77% | |
| Net Income YoY (latest Q) | ◆ 36.17% | 29.12% | -22.00% | 3.28% | 3.28% +1003% | |
| Profitability | ||||||
| EBITDA Margin | 20.26% | 25.34% | 20.43% | ◆ 32.61% | 25.34% -20% | |
| Net Income Margin | 10.23% | 13.57% | ◆ 15.98% | 15.29% | 15.29% -33% | |
| Return on Common Equity | ◆ 18.57% | 11.55% | 16.04% | 12.30% | 12.30% +51% | |
| Return on Capital Employed | ◆ 25.43% | 12.66% | 16.30% | 9.56% | 12.66% +101% | |
| Return on Assets | 9.79% | 6.90% | ◆ 11.26% | 4.82% | 6.90% +42% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.24× | 0.38× | ◆ 0.11× | 0.84× | 0.38× -37% | |
| Interest Coverage | 10.09× | 4.27× | ◆ 16.32× | 8.94× | 8.94× +13% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹9,204 Cr | ₹14,278 Cr | ₹14,712 Cr | ₹13,980 Cr | ₹14,278 Cr -36% | |
| Net Income | ₹941 Cr | ₹1,938 Cr | ₹2,351 Cr | ₹2,138 Cr | ₹2,138 Cr -56% | |
| Total Assets | ₹9,612 Cr | ₹28,080 Cr | ₹20,873 Cr | ₹44,312 Cr | ₹28,080 Cr -66% | |
| EPS | ₹48.77 | ₹46.35 | ₹192.51 | ₹63.92 | ₹63.92 -24% | |
| Book Value per Share | ₹262.5 | ₹401.19 | ₹1,200.25 | ₹519.56 | ₹519.56 -49% | |